Paion’s ‘ultra-short-acting’ anaesthetic Byfavo has received approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for use in procedural sedation.
The approval of Byfavo is based on data from a US-based Phase III clinical trial programme in procedural sedation